Patent ID: 6906037

Claim:
A pharmaceutical composition comprising a peptide-based construct of 8-14 amino acid moieties in length having heparin binding, heparin neutralizing, endothelial cell proliferation inhibiting, antiangiogenic LPS binding, LPS neutralization, or antimicrobial properties comprising: a sequence having the formula: α-χ-χ-α-χ-β-χ-α-R wherein, α is a hydrophilic basic amino acid moiety selected from the group consisting of lysine, arginine, histidine, ornithine, diamiriobutyric acid, citrulline, and para-amino phenylalanine; β is a hydrophilic neutral amino acid moiety selected from the group consisting of asparagine, glutamine, serine, threonine, tyrosine, hydroxyproline, and 7-hydroxy-tetrahydroisoquinoline carboxylic acid; χ is a hydrophobic amino acid moiety selected from the group consisting of alanihe, naphthylalanine, biphenylalanine, valine, leucine, isoleucine, proline, hydroxyproline, phenylalanine, tryptophan, methionirie, glycine, cyclohexylalanine, amino-isobutyric acid, norvaline, norleucine, tert-leucine, tetrahydroisoquinoline carboxylic acid, pipecolic acid, phenylglycine, homophenylalanine, cyclohexylglycine, dehydroleucine, 2, 2-diethylglycine, 1-amino-1-cyclopentane carboxylic acid, 1-amino-1-cyclohexane carboxylic acid, amino-benzoic acid, amino-naphthyl carbbxylic acid, γ-amino butyric acid, beta-alanine, difluorophenylalanine, fluorophenylalanine, nipecotic acid, aminobutyric acid, thienyl-alanine, and t-butyl-glycine; and R is an amino acid moiety selected from the group consisting of -χ, -χ-α, -χ-α-χ, χ-α-χ-β, -χ-α-χ-β-χ, -χ-α-χ-β-χ-α, -χ-β-χ-χ-β-χ, -NH 2 , -χ-NH 2 , -χ-α-NH 2 , -χ-α-χ-NH 2 , -χ-α-χ-β-NH 2 , -χ-α-χ-β-χ-NH 2 , -χ-α-χ-β-χ-α-NH 2 , and -χ-β-χ-χ-β-χ-NH 2 , and a pharmaceutically acceptable diluent, adjuvant, or carrier.